Posted: Tuesday, September 3, 2019
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, describes the immunotherapy KTE-X19, its proposed mechanism in relapsed or refractory chronic lymphocytic leukemia, and how it might be incorporated into a therapeutic plan.